1. Ding Z, White PF. Anesthesia for electroconvulsive therapy. Anesth Analg 2002; 94: 1351-64.
2. Khan A, Mirolo MH, Hughes D, Bierut L. Electroconvulsive therapy. Psychiatr Clin North Am 1993; 16: 497-513.
3. McCall WV, Kellner CH, Fink M. Convulsive therapy and the Journal of ECT: 30 years of publication and continuing. J ECT 2014; 30: 1-2.
4. Taylor S. Electroconvulsive therapy: a review of history, patient selection, technique, and medication management. South Med J 2007; 100: 494-8.
5. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004; 55: 301-12.
6. Food and Drug Administration, HHS. Neurological devices; reclassification of electroconvulsive therapy devices; effective date of requirement for premarket approval for electroconvulsive therapy devices for certain specified intended uses. Final order. Fed Regist 2018; 83: 66103-24.
7. Hermann RC, Dorwart RA, Hoover CW, Brody J. Variation in ECT use in the United States. Am J Psychiatry 1995; 152: 869-75.
8. Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, et al. Management of treatment-resistant depression in real-world clinical practice settings across Asia. Neuropsychiatr Dis Treat 2020; 16: 2943-59.
9. Xiang YT, Ungvari GS, Correll CU, Chiu HF, Lai KY, Wang CY, et al. Use of electroconvulsive therapy for Asian patients with schizophrenia (2001-2009): trends and correlates. Psychiatry Clin Neurosci 2015; 69: 489-96.
10. Lee JR, Park SJ, Lim JG, Yang HS. Ambulatory anesthetic care for electroconvulsive therapy (ECT) in psychiatric patients. Korean J Anesthesiol 2002; 43: 520-4.
11. Jaffe R. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging: a task force report of the American Psychiatric Association, 2nd ed. Am J Psychiatry 2002; 159: 331.
12. Fink M, Kellner CH, McCall WV. Optimizing ECT technique in treating catatonia. J ECT 2016; 32: 149-50.
13. Shapira B, Calev A, Lerer B. Optimal use of electroconvulsive therapy: choosing a treatment schedule. Psychiatr Clin North Am 1991; 14: 935-46.
14. Gill SP, Kellner CH. Clinical practice recommendations for continuation and maintenance electroconvulsive therapy for depression: outcomes from a review of the evidence and a consensus workshop held in Australia in May 2017. J ECT 2019; 35: 14-20.
15. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry 2015; 16: 76-95.
16. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49: 1087-206.
18. Franklin AD, Sobey JH, Stickles ET. Anesthetic considerations for pediatric electroconvulsive therapy. Paediatr Anaesth 2017; 27: 471-9.
19. Rasmussen K. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (second edition). J ECT 2002; 18: 58-9.
20. Sundsted KK, Burton MC, Shah R, Lapid MI. Preanesthesia medical evaluation for electroconvulsive therapy: a review of the literature. J ECT 2014; 30: 35-42.
21. Tess AV, Smetana GW. Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med 2009; 360: 1437-44. Erratum in. N Engl J Med 2011; 364: 1582.
22. Thompson JW, Weiner RD, Myers CP. Use of ECT in the United States in 1975, 1980, and 1986. Am J Psychiatry 1994; 151: 1657-61.
23. Wagner KJ, Möllenberg O, Rentrop M, Werner C, Kochs EF. Guide to anaesthetic selection for electroconvulsive therapy. CNS Drugs 2005; 19: 745-58.
24. Lafferty JE, North CS, Spitznagel E, Isenberg K. Laboratory screening prior to ECT. J ECT 2001; 17: 158-65.
25. Cristancho MA, Alici Y, Augoustides JG, O'Reardon JP. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep 2008; 10: 474-80.
26. Fernández-Candil J, Castelltort Mascó L, Fàbregas Julià N, Urretavizcaya Sarachaga M, Bernardo Arroyo M, Valero Castell R. Anaesthesia in electroconvulsive therapy. Special conditions. Rev Psiquiatr Salud Ment (Engl Ed) 2020; 13: 36-46.
27. Weinger MB, Partridge BL, Hauger R, Mirow A. Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: I. Effectiveness of pretreatment regimens on hemodynamics. Anesth Analg 1991; 73: 556-62.
28. Castelli I, Steiner LA, Kaufmann MA, Alfillé PH, Schouten R, Welch CA, et al. Comparative effects of esmolol and labetalol to attenuate hyperdynamic states after electroconvulsive therapy. Anesth Analg 1995; 80: 557-61.
29. Wells DG, Davies GG. Hemodynamic changes associated with electroconvulsive therapy. Anesth Analg 1987; 66: 1193-5.
30. Mental Health and Drug and Alcohol Office. Guidelines: ECT minimum standards of practice in NSW / NSW Health. North Sydney, Mental Health and Drug and Alcohol Office. 2010.
31. Larsen JR, Hein L, Strömgren LS. Ventricular tachycardia with ECT. J ECT 1998; 14: 109-14.
32. Price JW, Price JR, Perry TL. Excessive hypertension and pulmonary edema after electroconvulsive therapy. J ECT 2005; 21: 174-7.
33. Ring BS, Parnass SM, Shulman RB, Phelan J, Khan SA. Cardiogenic shock after electroconvulsive therapy. Anesthesiology 1996; 84: 1511-3.
34. Saito S, Kadoi Y, Iriuchijima N, Obata H, Arai K, Morita T, et al. Reduction of cerebral hyperemia with anti-hypertensive medication after electroconvulsive therapy. Can J Anaesth 2000; 47: 767-74.
35. Saito S, Miyoshi S, Yoshikawa D, Shimada H, Morita T, Kitani Y. Regional cerebral oxygen saturation during electroconvulsive therapy: monitoring by near-infrared spectrophotometry. Anesth Analg 1996; 83: 726-30.
36. Nott MR, Watts JS. A fractured hip during electro-convulsive therapy. Eur J Anaesthesiol 1999; 16: 265-7.
37. Sarpel Y, Toğrul E, Herdem M, Tan I, Baytok G. Central acetabular fracture-dislocation following electroconvulsive therapy: report of two similar cases. J Trauma 1996; 41: 342-4.
38. Edwards RM, Stoudemire A, Vela MA, Morris R. Intraocular pressure changes in nonglaucomatous patients undergoing electroconvulsive therapy. Convuls Ther 1990; 6: 209-13.
39. McCormick AS, Saunders DA. Oxygen saturation of patients recovering from electroconvulsive therapy. Anaesthesia 1996; 51: 702-4.
40. Labbate LA, Miller JP. Midazolam for treatment of agitation after ECT. Am J Psychiatry 1995; 152: 472-3.
41. Narang P, Ianovich F, Sarai SK, Lippmann S. Benefits of dexmedetomidine in management of post-ECT agitation. J ECT 2017; 33: 150-1.
42. Stein ALS, Sacks SM, Roth JR, Habis M, Saltz SB, Chen C. Anesthetic management during electroconvulsive therapy in children: a systematic review of the available literature. Anesth Analg 2020; 130: 126-40.
43. Wachtel LE. Treatment of catatonia in autism spectrum disorders. Acta Psychiatr Scand 2019; 139: 46-55.
44. Gilot B, Gonzalez D, Bournazeau JA, Barriére A, Van Lieferinghen P. [Case report: electroconvulsive therapy during pregnancy]. Encephale 1999; 25: 590-4. French.
45. Rose S, Dotters-Katz SK, Kuller JA. Electroconvulsive therapy in pregnancy: safety, best practices, and barriers to care. Obstet Gynecol Surv 2020; 75: 199-203.
46. Echevarría Moreno M, Martin Muñoz J, Sanchez Valderrabanos J, Vázquez Gutierrez T. Electroconvulsive therapy in the first trimester of pregnancy. J ECT 1998; 14: 251-4.
47. Brown NI, Mack PF, Mitera DM, Dhar P. Use of the ProSeal laryngeal mask airway in a pregnant patient with a difficult airway during electroconvulsive therapy. Br J Anaesth 2003; 91: 752-4.
48. Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Høie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health 2015; 18: 1-39.
51. Ramakrishnan VS, Kim YK, Yung W, Mayur P. ECT in the time of the COVID-19 pandemic. Australas Psychiatry 2020; 28: 527-9.
52. Luccarelli J, Fernandez-Robles C, Fernandez-Robles C, Horvath RJ, Berg S, McCoy TH, et al. Modified anesthesia protocol for electroconvulsive therapy permits reduction in aerosol-generating bag-mask ventilation during the COVID-19 pandemic. Psychother Psychosom 2020; 89: 314-9.
53. Limoncelli J, Marino T, Smetana R, Sanchez-Barranco P, Brous M, Cantwell K, et al. General anesthesia recommendations for electroconvulsive therapy during the Coronavirus disease 2019 pandemic. J ECT 2020; 36: 152-5.
54. MacPherson RD. Which anesthetic agents for ambulatory electro-convulsive therapy? Curr Opin Anaesthesiol 2015; 28: 656-61.
55. Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg 1995; 81: 596-602.
56. Cook A, Stevenson G, Scott AI. A survey of methohexitone use by anesthetists in the clinical practice of ECT in Edinburgh. J ECT 2000; 16: 350-5.
57. Mokriski BK, Nagle SE, Papuchis GC, Cohen SM, Waxman GJ. Electroconvulsive therapy-induced cardiac arrhythmias during anesthesia with methohexital, thiamylal, or thiopental sodium. J Clin Anesth 1992; 4: 208-12.
58. Saito S, Kadoi Y, Nara T, Sudo M, Obata H, Morita T, et al. The comparative effects of propofol versus thiopental on middle cerebral artery blood flow velocity during electroconvulsive therapy. Anesth Analg 2000; 91: 1531-6.
59. Tanaka N, Saito Y, Hikawa Y, Nakazawa K, Yasuda K, Amaha K. [Effects of thiopental and sevoflurane on hemodynamics during anesthetic management of electroconvulsive therapy]. Masui 1997; 46: 1575-9. Japanese.
60. Trzepacz PT, Weniger FC, Greenhouse J. Etomidate anesthesia increases seizure duration during ECT. A retrospective study. Gen Hosp Psychiatry 1993; 15: 115-20.
61. Eranti SV, Mogg AJ, Pluck GC, Landau S, McLoughlin DM. Methohexitone, propofol and etomidate in electroconvulsive therapy for depression: a naturalistic comparison study. J Affect Disord 2009; 113: 165-71.
62. Fredman B, d'Etienne J, Smith I, Husain MM, White PF. Anesthesia for electroconvulsive therapy: effects of propofol and methohexital on seizure activity and recovery. Anesth Analg 1994; 79: 75-9.
63. Geretsegger C, Rochowanski E, Kartnig C, Unterrainer AF. Propofol and methohexital as anesthetic agents for electroconvulsive therapy (ECT): a comparison of seizure-quality measures and vital signs. J ECT 1998; 14: 28-35.
64. Bailine SH, Petrides G, Doft M, Lui G. Indications for the use of propofol in electroconvulsive therapy. J ECT 2003; 19: 129-32.
65. Fear CF, Littlejohns CS, Rouse E, McQuail P. Propofol anaesthesia in electroconvulsive therapy. Reduced seizure duration may not be relevant. Br J Psychiatry 1994; 165: 506-9.
66. Parashchanka A, Schelfout S, Coppens M. Role of novel drugs in sedation outside the operating room: dexmedetomidine, ketamine and remifentanil. Curr Opin Anaesthesiol 2014; 27: 442-7.
67. Kavalali ET, Monteggia LM. How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol 2015; 20: 35-9.
68. Boylan LS, Haskett RF, Mulsant BH, Greenberg RM, Prudic J, Spicknall K, et al. Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other factors. J ECT 2000; 16: 3-18.
69. Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol 2020; 33: 506-11.
70. Mizrak A, Koruk S, Ganidagli S, Bulut M, Oner U. Premedication with dexmedetomidine and midazolam attenuates agitation after electroconvulsive therapy. J Anesth 2009; 23: 6-10.
71. Qiu Z, Zhou S, Zhang M, Guo N, Huang P, Xiang P, et al. Preventive effect of dexmedetomidine on postictal delirium after electroconvulsive therapy: a randomised controlled study. Eur J Anaesthesiol 2020; 37: 5-13.
72. Ishikawa T, Kawahara S, Saito T, Otsuka H, Kemmotsu O, Hirayama E, et al. [Anesthesia for electroconvulsive therapy during pregnancy--a case report]. Masui 2001; 50: 991-7. Japanese.
73. Fink M, Bailine S. Electroconvulsive therapy and managed care. Am J Manag Care 1998; 4: 107-12. quiz 113-4.
74. Fredman B, Smith I, d'Etienne J, White PF. Use of muscle relaxants for electroconvulsive therapy: how much is enough? Anesth Analg 1994; 78: 195-6.
75. Tang WK, Ungvari GS. Asystole during electroconvulsive therapy: a case report. Aust N Z J Psychiatry 2001; 35: 382-5.
76. Cooper RC, Baumann PL, McDonald WM. An unexpected hyperkalemic response to succinylcholine during electroconvulsive therapy for catatonic schizophrenia. Anesthesiology 1999; 91: 574-5.
77. Jaksa RJ, Palahniuk RJ. Attempted organophosphate suicide: a unique cause of prolonged paralysis during electroconvulsive therapy. Anesth Analg 1995; 80: 832-3.
78. Kelly D, Brull SJ. Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine? Can J Anaesth 1994; 41: 845-9.
79. Lui PW, Ma JY, Chan KK. Modification of tonic-clonic convulsions by atracurium in multiple-monitored electroconvulsive therapy. J Clin Anesth 1993; 5: 16-21.
81. Postaci A, Tiryaki C, Sacan O, Ornek D, Kalyoncu M, Dikmen B. Rocuronium-sugammadex decreases the severity of post-electroconvulsive therapy agitation. J ECT 2013; 29: e2-3.
82. Wolkenstein K, Ali S, Chacko R, Nabi Q, Carter L. Rocuronium-sugammadex and intubation used for an electroconvulsive therapy patient. J ECT 2020; 36: e15-6.
84. Weinger MB, Partridge BL, Hauger R, Mirow A, Brown M. Prevention of the cardiovascular and neuroendocrine response to electroconvulsive therapy: II. Effects of pretreatment regimens on catecholamines, ACTH, vasopressin, and cortisol. Anesth Analg 1991; 73: 563-9.
85. Saito S. Anesthesia management for electroconvulsive therapy: hemodynamic and respiratory management. J Anesth 2005; 19: 142-9.
86. Kelway B, Simpson KH, Smith RJ, Halsall PJ. Effects of atropine and glycopyrrolate on cognitive function following anaesthesia and electroconvulsive therapy (ECT). Int Clin Psychopharmacol 1986; 1: 296-302.
87. Avramov MN, Stool LA, White PF, Husain MM. Effects of nicardipine and labetalol on the acute hemodynamic response to electroconvulsive therapy. J Clin Anesth 1998; 10: 394-400.
88. O'Flaherty D, Husain MM, Moore M, Wolff TR, Sills S, Giesecke AH. Circulatory responses during electroconvulsive therapy. The comparative effects of placebo, esmolol and nitroglycerin. Anaesthesia 1992; 47: 563-7.
89. Parab AL, Chaudhari LS, Apte J. Use of nitroglycerin ointment to prevent hypertensive response during electroconvulsive therapy--a study of 50 cases. J Postgrad Med 1992; 38: 55-7.
90. Villalonga A, Planella T, Castillo J, Hernández C, Cabrer C, Mañalich M, et al. [Nitroglycerin spray in the prevention of hypertension induced by electroconvulsive therapy]. Rev Esp Anestesiol Reanim 1989; 36: 264-6. Spanish.
91. Devanand DP, Malitz S, Sackeim HA. ECT in a patient with aortic aneurysm. J Clin Psychiatry 1990; 51: 255-6.
92. Drop LJ, Bouckoms AJ, Welch CA. Arterial hypertension and multiple cerebral aneurysms in a patient treated with electroconvulsive therapy. J Clin Psychiatry 1988; 49: 280-2.
93. Levin L, Wambold D, Viguera A, Welch CA, Drop LJ. Hemodynamic responses to ECT in a patient with critical aortic stenosis. J ECT 2000; 16: 52-61.
94. Sudha S, Andrade C, Anand A, Guido S, Venkataraman BV. Nitroprusside and ECS-induced retrograde amnesia. J ECT 2001; 17: 41-4.
95. Petrides G, Maneksha F, Zervas I, Carasiti I, Francis A. Trimethaphan (Arfonad) control of hypertension and tachycardia during electroconvulsive therapy: a double-blind study. J Clin Anesth 1996; 8: 104-9.
96. Fu W, Stool LA, White PF, Husain MM. Acute hemodynamic responses to electroconvulsive therapy are not related to the duration of seizure activity. J Clin Anesth 1997; 9: 653-7.
97. MacPherson R, Marroquin-Harris M, Gálvez V, Tor P, Loo C. The effect of adjuvant remifentanil with propofol or thiopentone on seizure quality during electroconvulsive therapy. Anaesth Intensive Care 2016; 44: 278-80.
98. Akcaboy ZN, Akcaboy EY, Yigitbasł B, Bayam G, Dikmen B, Gogus N, et al. Effects of remifentanil and alfentanil on seizure duration, stimulus amplitudes and recovery parameters during ECT. Acta Anaesthesiol Scand 2005; 49: 1068-71.
99. Andersen FA, Arsland D, Holst-Larsen H. Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy. Acta Anaesthesiol Scand 2001; 45: 830-3.
100. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth 2020; 124: 44-62.
101. van Zijl DH, Gordon PC, James MF. The comparative effects of remifentanil or magnesium sulfate versus placebo on attenuating the hemodynamic responses after electroconvulsive therapy. Anesth Analg 2005; 101: 1651-5.
103. Osler M, Rozing MP, Christensen GT, Andersen PK, Jørgensen MB. Electroconvulsive therapy and risk of dementia in patients with affective disorders: a cohort study. Lancet Psychiatry 2018; 5: 348-56.
104. Tzabazis A, Schmitt HJ, Ihmsen H, Schmidtlein M, Zimmermann R, Wielopolski J, et al. Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option. J ECT 2013; 29: 189-95.